In HCC patients treated with curative resection and ablation, there are many ongoing trials using ICBs, targeting PD-(L)1, VEGF, and CTLA-4, in adjuvant settings after curative therapies. This evidence concerns the gene CD274 and hepatocellular carcinoma.